Association between Lower Urinary Tract Symptoms/Benign Prostate Hyperplasia and metabolic syndrome in Indonesian men
Short Podium Session
1:30 PM - 2:40 PM
dr. Dyandra Parikesit (1), DR. Fiastuti Witjaksono (2), PhD Chaidir Arif Mochtar (1), DR. Nur Rasyid (1), PhD Agus Rizal A. H. Hamid (1)
(1) Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Central Jakarta, Indonesia, (2) Department of Nutrition, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Central Jakarta, Indonesia
Controversial findings were found in various previous studies in regards to the relationship between LUTS/BPH and Metabolic Syndrome (MetS). The aim of this study is to evaluate the association between LUTS/BPH and MetS in Indonesian men.
A total of 227 patients with histologic proven BPH were included in this study. Body Mass Index (BMI), Waist Circumference (WC), prostate volume, and International Prostate Symptom Score (IPSS) were measured. Prostate Specific antigen (PSA), fasting blood glucose (FBG), triglyceride (TG), High Density Lipoprotein (HDL) were tested. MetS were diagnosed using The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III). IPSS was subcategorized as irritative and obstructive scores and patients were classified into 4 groups according to the number of exhibited MetS components (less than 3, 3, 4, and 5). Spearman’s correlation was used to analyses the association between all continuous variable. Mean difference between risk factor groups were analysed using One-way ANOVA for normally distributed variables and Kruskall Wallis for abnormally distributed variables.
MetS was diagnosed in 87 (38,3%) patients. Patients with MetS have significantly higher BMI, WC, systolic blood pressure, triglyceride, fasting blood glucose, IPSS irritative score, total IPSS score, and lower HDL cholesterol. Patients with central obesity have significantly higher risk of having moderate-severe LUTS (RR 1.16, 95% CI: 1.01 – 1.4, p = <0.05) and decreased risk in developing higher PSA level (PSA 20) (RR 0.41, CI 95%: 0. 23 – 0.74, P = <0.001)
MetS has limited impact towards LUTS/BPH. Association and increase risk of LUTS/BPH were only seen in patients with central obesity.